ERBB2 and adenocarcinoma: The ToGA trial, which added trastuzumab (monoclonal antibody) to standard chemotherapy, showed improved survival of patients with HER2-positive advanced G/GEJ adenocarcinoma and brought these patients into a new era of HER2-targeted therapy.